(0.13%) 5 138.25 points
(0.09%) 38 476 points
(0.21%) 17 883 points
(-0.24%) $83.65
(1.72%) $1.956
(0.13%) $2 350.30
(0.46%) $27.66
(1.61%) $936.90
(-0.17%) $0.933
(-0.27%) $10.99
(-0.29%) $0.798
(1.19%) $92.97
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.96%
@ $16.78
发出时间: 15 Feb 2024 @ 00:57
回报率: -3.52%
上一信号: Feb 14 - 04:50
上一信号:
回报率: 3.13 %
Live Chart Being Loaded With Signals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease...
Stats | |
---|---|
今日成交量 | 305 658 |
平均成交量 | 750 419 |
市值 | 793.19M |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-1.280 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.69 |
ATR14 | $0.0140 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Mills Kenneth T. | Buy | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Stock Options (Right to Buy) |
2024-03-19 | Vasista Vittal | Buy | 20 041 | Common Stock |
2024-03-19 | Vasista Vittal | Sell | 20 041 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
56.21 |
Last 99 transactions |
Buy: 2 306 609 | Sell: 467 606 |
音量 相关性
Regenxbio Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Regenxbio Inc 相关性 - 货币/商品
Regenxbio Inc 财务报表
Annual | 2023 |
营收: | $90.24M |
毛利润: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2023 |
营收: | $90.24M |
毛利润: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2022 |
营收: | $112.72M |
毛利润: | $58.18M (51.61 %) |
EPS: | $-6.50 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $3.01 |
Financial Reports:
No articles found.
Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。